Canaccord Genuity Reaffirms Buy Rating on Avanir Pharmaceuticals (AVNR)

By admin | 7 years ago

Avanir Pharmaceuticals (NASDAQ: AVNR)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Wednesday.

Avanir Pharmaceuticals opened at 2.76 on Wednesday. Avanir Pharmaceuticals has a 1-year low of $1.77 and a 1-year high of $4.80. The company’s market cap is $366.2 million.

Avanir Pharmaceuticals last released its earnings data on Tuesday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.01. The company’s revenue for the quarter was up 2117.8% on a year-over-year basis. Analysts expect that Avanir Pharmaceuticals will post $-0.10 EPS next quarter.

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders.

About the author